Quetiapine in Social Anxiety Disorder

Completed · Phase 2/Phase 3

Conditions studied: Social Anxiety Disorder

In brief

The purpose of the study is to examine the effectiveness and tolerability of quetiapine for the treatment of social anxiety disorder (SAD). The hypothesis is that quetiapine will be effective and well-tolerated for patients with social anxiety disorder.

Key facts

Study ID

NCT00215254

Run by

Duke University

People needed

15

Starts

2004-03-01

Expected to finish

2006-02-01

Last updated by the study team

2006-12-19

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• adult outpatients 18-65 years of age
• primary diagnosis of social anxiety disorder, using DSM-IV criteria
• minimum CGI severity score of 4 at baseline
• minimum BSPS score of 20 at baseline
• written informed consent
• negative serum pregnancy test for women of childbearing potential

You may not qualify if…

• current DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, or cognitive disorder due to a general medical condition
• any current primary anxiety disorder other than SAD or current primary depression
• history of substance abuse or dependence with the last 6 months
• suicide risk or serious suicide attempt within the last year
• clinically significant medical condition or laboratory abnormality
• women of childbearing potential who are unwilling to practice an acceptable method of contraception
• concomitant medication use for psychotropic purposes
• history of hypersensitivity to quetiapine

Where it is running

• Duke University Medical Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.